Cargando…

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?

Detalles Bibliográficos
Autores principales:	Park, Jihye, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444114/ https://www.ncbi.nlm.nih.gov/pubmed/34521776 http://dx.doi.org/10.5009/gnl210345

Ejemplares similares

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
por: Park, Jihye
Publicado: (2022)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Incidence and Prevalence of Inflammatory Bowel Disease across Asia
por: Park, Jihye, et al.
Publicado: (2021)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
por: Kothari, Mansi M, et al.
Publicado: (2017)

Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
por: Han, So Jung, et al.
Publicado: (2023)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western
por: Seo, Hyungil, et al.
Publicado: (2016)

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
por: Chaparro, María, et al.
Publicado: (2019)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
por: Park, Jihye
Publicado: (2023)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
por: Park, Jihye, et al.
Publicado: (2021)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
por: Lee, Ko Eun, et al.
Publicado: (2019)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
por: Kang, Elise, et al.
Publicado: (2018)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
por: Nawaz, Ahmad, et al.
Publicado: (2023)

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
por: Lee, Jae Yong, et al.
Publicado: (2021)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
por: Song, Joo Hye, et al.
Publicado: (2021)

Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
por: Chu, Cong-Qiu
Publicado: (2021)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
por: Lee, Jang Wook, et al.
Publicado: (2016)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
por: Hong, Seung Wook, et al.
Publicado: (2021)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease
por: Yau, Tung On, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56uibfu9d1i7etucjheu23ban6